Cite

HARVARD Citation

    Zhang, W. et al. (2020). Absolute Bioavailability of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies. Clinical pharmacology in drug development. 9 (4), pp. 496-504. [Online]. 
  
Back to record